항콕시듐제 시장 : 약제 클래스별, 약효별, 동물 유형별, 유통 채널별, 세계 예측(2024-2032년)

Global Anticoccidial Drugs Market will achieve a 4.1% CAGR between 2024 and 2032, driven by rising awareness of animal health and a shift towards natural and alternative solutions. As consumers and producers increasingly prioritize animal welfare, there is a growing demand for effective, non-antibiotic treatments. This trend promotes the development and adoption of natural anticoccidial options that offer safer and more sustainable disease management. The focus on enhancing animal health while minimizing antibiotic use aligns with evolving market needs, contributing to significant industry growth.

For instance, in April 2022, Amlan International introduced two new natural alternatives to antibiotics for livestock and poultry: Phylox(R) Feed and NeutraPath(R). These products enhance intestinal health and improve production economics without using antibiotics. These new products offer enhanced intestinal health and production benefits, which may influence market dynamics by promoting natural solutions and potentially expanding options for livestock and poultry management.

The anticoccidial drugs industry is fragmented based on drug class, drug action, animal type, distribution channel, and region.

The coccidiocidal segment will see a considerable surge by 2032, attributed to its effectiveness in killing coccidia parasites and preventing the spread of coccidiosis. These drugs play a crucial role in managing and controlling infections in livestock, poultry, and other animals, which helps to maintain productivity and reduce economic losses. The high efficacy of coccidiocidal drugs in treating existing infections and preventing new outbreaks drives their dominance in the industry, as they are essential for ensuring animal health and optimizing agricultural output.

The livestock animals segment will garner remarkable gains by 2032 due to the critical need for effective disease management in animal agriculture. Anticoccidial drugs are essential for preventing and treating coccidiosis, a parasitic infection that affects livestock and can lead to major economic losses. As the demand for meat and dairy products rises, farmers and producers increasingly rely on these drugs to maintain animal health and productivity. The focus on improving livestock welfare and reducing disease outbreaks supports the segment's dominance.

Europe anticoccidial drugs market will secure a moderate CAGR through 2032, owing to its stringent regulatory standards, advanced veterinary practices, and high livestock production levels. The region's focus on maintaining rigorous animal health protocols and preventing disease outbreaks drives demand for effective anticoccidial solutions. Besides, Europe's commitment to integrating innovative treatments and ensuring high-quality animal care contributes to its substantial market share. This combination of regulatory support, industry standards, and technological progress makes Europe a notable contributor to the global anticoccidial drugs industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of coccidiosis
    • 3.2.1.2 Growing livestock population
    • 3.2.1.3 Rising demand for animal protein
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of drug development
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Synthetic compounds
• 5.3 Polyether antibiotics or ionophores

Chapter 6 Market Estimates and Forecast, By Drug Action, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Coccidiostatic
• 6.3 Coccidiocidal

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Poultry
  • 7.3.3 Other livestock animals

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals & pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Bayer AG
• 10.2 Boehringer Ingelheim International GmbH
• 10.3 Ceva
• 10.4 Cronus Pharma LLC
• 10.5 Elanco Animal Health Incorporated
• 10.6 Huvepharma EOOD
• 10.7 Impextraco NV
• 10.8 Merck & Co., Inc.
• 10.9 Phibro Animal Health Corporation
• 10.10 Vetoquinol SA
• 10.11 Virbac SA
• 10.12 Zoetis Inc.